Dulaglutide for Fat Loss
Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.
Why Dulaglutide for fat loss?
Dulaglutide (Trulicity, Eli Lilly, FDA-approved 2014) is a GLP-1 analog covalently linked to a human IgG4 Fc fragment, giving a half-life of ~5 days. The REWIND trial demonstrated CV benefit in T2DM with and without established CVD. Less weight loss than semaglutide/tirzepatide but strong cardio-metabolic profile.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Dulaglutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Once-weekly dosing
- HbA1c reduction
- CV risk reduction (REWIND)
Reference dosing by bodyweight
Anchored to the most-cited research dose (750 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 468–633 mcg |
| 60–75 kg / 132–165 lb | 574–776 mcg |
| 75–90 kg / 165–198 lb | 701–949 mcg |
| 90–105 kg / 198–231 lb | 829–1121 mcg |
| >105 kg / >231 lb | 956–1294 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Diarrhea
- Injection-site reactions
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.